<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref96">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>McBride</surname>
    <given-names>J. M.</given-names>
   </name>
   <name>
    <surname>Lim</surname>
    <given-names>J. J.</given-names>
   </name>
   <name>
    <surname>Burgess</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Deng</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Derby</surname>
    <given-names>M. A.</given-names>
   </name>
   <name>
    <surname>Maia</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2017</year>). 
  <article-title>Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model</article-title>. 
  <source>Antimicrob. Agents Chemother.</source>
  <volume>61</volume>:
  <fpage>e01154-17</fpage>. 
  <pub-id pub-id-type="doi">10.1128/AAC.01154-17</pub-id>, PMID: 
  <?supplied-pmid 28807912?>
  <pub-id pub-id-type="pmid">28807912</pub-id>
 </mixed-citation>
</ref>
